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Summary Introduction
A novel point mutation in the lysosomal acid sphingo-
myelinase gene has been identified in the recently re-
ported Serbian family with a clinically and biochemi-
cally atypical intermediate form of Niemann-Pick dis-
ease. The mutation was a T1"71-G transversion resulting
in substitution of glycine for normal tryptophan at
amino acid residue 391. The coding sequence was other-
wise normal. All of the five affected individuals were
almost certainly homoallelic, and both of the two obli-
gate heterozygotes studied also carried the same muta-
tion. This mutation is therefore likely to be directly asso-
ciated with the atypical phenotype of these patients. Ex-
pression in COS-1 cells suggested a higher residual
activity than that in cultured fibroblasts. A recently de-
veloped high-affinity rabbit antihuman sphingomy-
elinase antibody allowed us to study for the first time
the biosynthesis, processing, and targeting of a mutant
sphingomyelinase by metabolic labeling of cultured fi-
broblasts. The mutant enzyme protein was normally
synthesized, processed, and routed to the lysosome but
was apparently unstable and degraded rapidly once it
reached the lysosome. Together with the finding of the
relatively high residual activity in COS-1 cells, we inter-
pret our observations to mean that instability and rapid
breakdown of the mature mutant enzyme protein, due
to the mutation rather than direct inactivation of the
catalytic activity, is the primary mechanism for the defi-
ciency of sphingomyelinase activity in these patients. A
high prevalence of this mutation in the Serbian popula-
tion is likely, since the family pedigree indicates that
members from four reportedly unrelated families must
have contributed the same mutation.
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Niemann-Pick disease is an autosomal recessive lyso-
somal storage disorder caused by a primary deficiency
of acid sphingomyelinase (ASM) [E.C.3.1.4.12], re-
sulting in massive tissue accumulation of sphingomyelin
(Schuchman and Desnick 1995). Classically, two allelic
subtypes with distinct clinical phenotypes have been de-
lineated: a severe neurodegenerative infantile form lead-
ing to death by 2-3 years of age (Niemann-Pick disease
type A), and a chronic, nonneuronopathic form (Nie-
mann-Pick disease type B) (Crocker 1961). An interme-
diate, subacute form has also been reported, including
rarer patients who satisfy the criteria for Niemann-Pick
disease type B but with additional signs of mild neuronal
involvement, such as retinal storage, peripheral neurop-
athy, mild neurological signs, or psychiatric disorders
(Spence and Callahan 1989). The molecular or enzymo-
logical basis for this broad phenotypic heterogeneity is
not yet clear. Cerebral storage of sphingomyelin has
been demonstrated in type A but not in type B patients,
in spite of essentially similar, very low, residual sphingo-
myelinase activities measured in brain tissue by the clas-
sical in vitro method (Spence and Callahan 1989). A
normal Michaelis-Menten constant was found in placen-
tal enzyme partially purified from a type A fetus (Rous-
son et al. 1987). This mutant enzyme protein cross-re-
acted with a polyclonal antibody against the normal
sphingomyelinase (Rousson et al. 1987). Limited studies
indicated the presence of immunologically cross-reactive
material in crude cell homogenates of both type A and
type B patients (Rousson et al. 1986; Callahan and Jobb
1988). On the other hand, cultured fibroblasts from clas-
sical type B patients can hydrolyze exogenously added
sphingomyelin at significantly higher rates than those
from type A patients (Beaudet and Manschrek 1982;
Vanier et al. 1985). The availability of the sphingomyeli-
nase cDNA and the gene (Quintern et al. 1987, 1989;
Schuchman et al. 1991, 1992) has made it possible to
study the precise molecular defects in patients. To date,
12 mutations responsible for Niemann-Pick disease have
been reported, among which are 3 with a high preva-
lence in Ashkenazi Jewish type A and 1 in North African
type B patients (Ferlinz et al. 1991; Levran et al. 1991a,
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Figure I Family pedigree (simplified from Sperl et al. 1994).
Filled symbols indicate affected individuals, and half-filled symbols
obligate heterozygotes who were tested. Clinical, neurophysiological,
and laboratory data of the patients have been reported under the same
numbering in Sperl et al. 1994. Patient 111/2 was not included in the
present investigation.
1991b, 1992, 1993a, 1993b; Takahashi et al. 1992a,
1992b; Vanier et al. 1993). Several point mutations
among which are splice-site mutations associated with
a type A or B phenotype and one three-base deletion
characteristic of a type B phenotype are thus far known.
Mutations can cause deficient steady-state ASM activity
not only due to inactivation of the catalytic activity but
also due to abnormal processing and stability of the
enzyme protein. However, no processing studies of mu-
tant sphingomyelinase have yet been available, due to
the lack of suitable anti-ASM antibodies. Anti-ASM an-
tibodies suitable for processing studies have been devel-
oped recently and have been used for studies of normal
sphingomyelinase (Ferlinz et al. 1994; Hurwitz et al.
1994b).
We recently described a Serbian family with six mem-
bers affected by an atypical intermediate form of Nie-
mann-Pick disease with a visceral course and an addi-
tional macular halo syndrome (Sperl et al. 1994). We
report here identification of a novel point mutation in
the ASM gene responsible for the disease in this family.
All affected members examined were almost certainly
homoallelic for the mutation. Synthesis and processing
of this mutant enzyme protein were also studied in cul-
tured fibroblasts.
Material and Methods
Subjects and Biological Material
The family pedigree (fig. 1) includes six patients with
an intermediate form of Niemann-Pick disease, all mem-
bers of the same clan with its roots in a small village of
Serbia. They showed a visceral course of the disease with
additional retinal changes (macular halos) indicative of
neuronal storage and a very low degradation rate of
sphingomyelin in skin fibroblasts. Their detailed clinical
and enzymatic phenotype has been published recently
(Sperl et al. 1994). The present study included seven
subjects: one affected woman (patient III/1), her four
children, three of them affected (patients IV/4, IV/5, and
IV/6), her supposedly unrelated husband, and an af-
fected second degree cousin (patient IV/3). Blood sam-
ples from patient IV/3 were provided by Dr. W. Sperl,
Innsbruck. Skin fibroblast cultures from all other sub-
jects were previously supplied by Dr. U. Wiesmann,
in -1 %-- t T T_ _ _L T__6 ~Bern, and Dr. (S. Utermann, lnnsbruck.
Material
DNA-modifying enzymes and N-[1-(2-3-Dioleo-
yloxy)propyl]-N,N,N-trimethyl-ammonium methylsul-
fate (DOTAP) lipofection reagent were obtained from
Boehringer, cell culture media and reverse transcriptase
from Gibco-BRL, and Taq-DNA polymerase from
Cetus-Perkin Elmer. Radioisotopes were purchased
from Amersham. A Sequenase version 2.0 kit was ob-
tained from USB, and coated magnetic beads for DNA
single-strand and mRNA isolation were obtained from
Dynal. All other standard chemicals were of the highest
quality available. The preparation and characterization
of the anti-ASM antibody have been reported elsewhere
(Hurwitz et al. 1994b).
RNA Extraction, cDNA Synthesis, and PCR Amplification
Total RNA and genomic DNA from fibroblasts and
blood was prepared according to standard protocols
(Ausubel et al. 1987; Sambrook et al. 1989). mRNA
was isolated by incubation of total RNA with oligo-
dT-coated magnetic beads and subsequent separation of
solid-phase-bound mRNA by magnetic attraction (Dy-
nal). Reverse transcription (200 U MuML V-RNase H-
reverse transcriptase, 43°C, 60 min) of 2 gg mRNA to
partial cDNAs was performed using 20 pmol of an inter-
nal sequence-specific primer. Northern analysis of 1 ,ug
of poly A+RNA was done with a full-length sphingomy-
elinase cDNA as the probe.
PCR amplification of the two portions of cDNAs was
done with a primer set consisting of a 5'-biotinylated
and a normal oligonucleotide, each (Albio/A2 and B1/
B2bio, in table 1). This yielded two overlapping PCR
products spanning the total protein-coding sequence as
well as most of the 3'-UTR. Amplification of 1 jg of
cellular DNA was carried out using an intronic 3'-sense
primer and a 5'-biotinylated antisense primer (I/B2bio
in table 1), with 30 cycles of heat denaturation at 95°C
for 30 s, annealing at 54°C for 2 min, and extension at
720C for 2.5 min. The amplified PCR products were
evaluated by agarose gel electrophoresis and were subse-
quently purified by extraction of excised bands using
silicon-beads (Qiagen).
DNA Sequence Analysis
Purified biotinylated PCR DNA was bound to Dyna-
beads M280-Streptavidin and the nonbiotinylated
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Albio .......... -29/-11 5'-Biotin-CGAACCAGCCCCGTGTAGG-3'
A2b .......... 1083/1063 5'-GAGGGTGCGCAGGGCYTCGGC-3'
B1 .......... 761/778 5'-TGAGGACCCTGGAGAGCC-3'
B2b .......... 1984/1967 5'-GTGGATTCACCGGATGATCTTGCCT-3'
B2biob .......... 1979/1967 5'-Biotin-TTCACCGGATGATCTTGCCT-3'
S .......... 1070/1087 5'-CCTGCGCACCCTCAGAAT-3'
Xb .......... 1183/1159 5'-TGATCAAGAGCCCGAAGTTCTCACG-3'
Y .......... 1159/1183 5'-CGTGAGAAC7TCGGGCTCTTGATCA-3'
I .......... intron 2 5'-ataagcttggaacaagtgttgacctc-3'
a Counted from the adenosine residue of the first putative initiation codon. Sequences given in upper-case
characters are exon sequences, and those in lower case are intron sequences. The underlined areas were
altered from the natural sequences in order to generate new restriction sites.
b Oligonucleotides corresponding to the antisense strand of DNA.
strand released essentially according to the manufactur-
er's instruction (Dynal). Solid phase-bound single-
stranded DNA, as well as soluble DNA, were neutralized
and sequenced by the chain-termination method (Sanger
et al. 1977) using Sequenase version 2.0.
Site-Directed Mutagenesis of cDNA by Overlap Extension
PCR amplification of wild-type cDNA was performed
using two sets of primers consisting of a wild-type-de-
rived and -mutated primer (B1/X and Y/B2, in table 1)
(Ho et al. 1989). The resulting purified PCR products,
identical with respect to the short DNA portion that
contained the mutated oligonucleotide, served further
as template for the second PCR using the nonmutated
3' and 5' flanking oligonucleotides (B1/B2) as primers
(table 1). Similar cycling conditions were used for the
first and second PCR of the overlap extension method
using 30 cycles with 30 s denaturation at 95C, 1 min
annealing at 52°C, and 1.5 min extension at 72°C. The
internal BstEII-DNA portion of the wild-type DNA was
substituted by the corresponding mutated DNA and fi-
nally ligated into the eukaryotic expression vector
p91023(B) (Kaufman et al. 1989).
COS-I Cell Expression
On the day before transfection, -5 x 105 COS-1 cells
were plated on 21-cm2 dishes. The transfections with
DOTAP as lipofection reagent (Boehringer-Mannheim)
were carried out by using 7 gg of pure plasmid DNA
for each dish. During the initial 6-h period, the cells
were maintained under OptiMEM medium (Gibco-
BRL) without supplements. Forty-eight hours after the
transfection the cells were harvested and assayed for
acid sphingomyelinase activity, using [3H] choline-la-
beled sphingomyelin (Quintern et al. 1989).
Sphingomyelinase Radiolabeling and Immunoprecipitation
Confluent cultured skin fibroblasts (25-cm2 flasks)
were starved for 1 h in a methionine-free DMEM me-
dium containing 4% dialyzed FCS. Labeling was initi-
ated by addition of 150 gCi of L-[35S]-methionine in 1
ml (>3000 Ci/mmol). After varying pulse periods,
chases were conducted by addition of L-methionine to
a final concentration of 10 mM. Cell extracts were pre-
pared with phosphate-buffered saline containing 1%
Nonidet P-40, 10 mg/ml ovalbumin, 2 mM phenylmeth-
ylsulfonylfluoride (PMSF), 5 mM iodoacetamide, 2 mM
EDTA, and 1 gg/ml leupeptin and pepstatin, each. Im-
munoprecipitation was performed using rabbit anti-
ASM antiserum as described elsewhere (Hurwitz et al.
1994b). Immunoprecipitated proteins were analyzed by
SDS-polyacrylamide gel electrophoresis using a 10%
slab gel. The gels were impregnated with Amplify (Am-
ersham) for fluorography.
Results
Identification of the Trp39 I Gly Mutation
The complete ASM-encoding cDNA segment, as well
as parts of the 5'- and 3'-flanking regions of proband IV/
6, were amplified and directly sequenced. This analysis
revealed a novel mutation, a T171-G transversion (nu-
cleotides counted from the A of the first putative initia-
tion codon, ATG), resulting in a substitution of glycine
(GGG) for normal tryptophan (TGG) at amino acid po-
sition 391 (Trp391Gly) (fig. 2). The remainder of the
protein-coding sequence was entirely normal. Northern
analysis of this patient did not show significant aberra-
tions in quantity and size of mRNA, compared with
normal control cells (data not shown). Sequence analysis
of this region in the six other members of the family
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Figure 2 Mutation analysis of PCR amplified genomic DNA
surrounding the point mutation of normal and an individual afflicted
with Niemann-Pick disease. A single nucleotide transversion, T-OG, at
position 1171 is indicated by an asterisk (*). Probands expressing
clinical manifestations were exclusively homoallelic (illustration repre-
sents DNA sequence derived from genomic DNA of proband IV/5,
whereas two oligate heterozygotes were found to be carriers of the
mutant allele.
studied indicated that all individuals carried at least one
Trp391Gly allele. Only the sequence containing this mu-
tation was present in this region of the genome in the
affected probands IIV/1, IV/4, IV/5, and IV/6 and their
affected cousin, patient IV/3. The healthy husband of
patient ITI/1 and her unaffected son carried only one
allele with this mutation, in good accordance with inter-
mediate sphingomyelinase activities (data not shown)
and the obligate heterozygote status of these two indi-
viduals.
Expression of the Trp39 I Gly Mutant Allele in COS-I Cells
The effect of the nucleotide substitution on the cata-
lytic activity of the resulting protein was assessed by
transient expression in COS-1 cells of cDNA containing
the T1171-G transversion generated by the overlap ex-
tension method (pASM391). As shown in table 2, sphin-
gomyelinase activity measured in COS-1 cell homoge-
nates transfected with the mutagenized DNA by an in
vitro detergent-containing assay showed a residual activ-
Table 2
Transient Expression of Acid Sphingomyelinase in COS- I Cells
Acid Sphingomyelinase Activity
Source (nmollhlmg homogenate protein ± SD)
COS-1 cells ................ 10.5 ± 1.4
p91023 (B) ................ 10.1 ± 0.7
pASMas (antisense) ......... 8.0 ± 1.1
pASMs (sense) ................ 68.2 ± 4.6
pASM391as (antisense) ... 8.4 ± 0.9
pASM391s (sense) ........... 15.4 ± 1.6
NoTE.-The values represent the mean of three independent experi-
ments, each using a different batch of recombinant DNA.
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ity of 6%-10% compared with that in wild-type
transfectants. This level of residual activity appeared
higher than the 1%-2% values found in cultured fibro-
blasts from the homozygous patients (Sperl et al. 1994;
present study).
Metabolic Labeling and Immunoprecipitation
Pulse-chase studies (1-h pulse and 2- or 6-h chase)
revealed that the 75-kDa ASM form that lacks signifi-
cant catalytic activity (Ferlinz et al. 1994; Hurwitz et al.
1994b) was present in similar amounts in the mutant
and control fibroblasts both in cellular extracts as well
as in the medium (fig. 3). In mutant cells, the early pro-
teolytic processing, which partially converts the propro-
form to the 72-kDa precursor and the 57-kDa form, was
also found to be normal. However, no mature lysosomal
ASM including the 70-kDa and the 50-kDa form, which
normally account for most of the enzyme activity, could
be detected in the mutant cells (fig. 3).
Discussion
Mutations in at least one allele have been reported to
date in nearly 50 patients with Niemann-Pick disease,
all of whom belong to the classical A or B phenotypes.
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A majority of the type A patients so far studied were of
Ashkenazi Jewish descent. In that population, two major
(R496L and L302P) and one minor (fsP330) mutations
accounted for 65% of the 52 tested alleles (Levran et al.
1991a, 1992, 1993b). The seven additional mutations
identified in six other families with type A patients ap-
pear sporadic (Ferlinz et al. 1991; Takahashi et al.
1992b; Levran et al. 1993a). Only two mutations associ-
ated with typical type B Niemann-Pick disease have so
far been reported. A three-base deletion, R(608), very
common (26/30 alleles) in patients from Northern Africa
(Vanier et al. 1993), may also be found in Ashkenazi
Jewish type B patients (Levran et al. 1991b), and more
generally in patients from the Mediterranean region
(M. T. Vanier, S. Duthel, and R. Rousson, unpublished
data). A homoallelic S436R substitution was found in
the only Japanese type B patient studied so far (Taka-
hashi et al. 1992a).
The present study identified the first mutation in pa-
tients with an intermediate "subacute" phenotype
(Spence and Callahan 1989). All of the five patients
studied appeared to be homoallelic, on the basis of the
sequencing data on genomic DNA. Although the data
themselves do not rigorously exclude a heteroallelic state
of the W391G mutation on one allele and a major dele-
tion on the other, careful pedigree analysis and other
pieces of evidence indicate that such a possibility is
highly unlikely. The W391G mutation was present not
only in all of the five patients but also in two obligate
carrier individuals, the husband of an affected mother,
and one of her offsprings. One of her affected children
showed normal size and quantity of sphingomyelinase
mRNA, a finding that provides support for the claim
that this child is homoallelic for the W391G mutation.
The distribution of the W391G mutation in the pedigree
(fig. 1) indicates that four reportedly unrelated families
contributed this mutation. All patients exhibited the
same atypical intermediate phenotype. These findings
collectively indicate that the W391G mutation occurs in
high frequency in the Serbian population and that the
mutation is directly associated with this atypical clinical
presentation. A study is underway to determine whether
other unrelated patients with a similar phenotype may
have the same mutation.
When transiently expressed in COS-1 cells, the mu-
tant cDNA, W391G, exhibited an apparently higher re-
sidual activity (6% -10% of control) than that in intact
cultured fibroblasts from patients (1 %-2%). This result
suggested that the mutation may not directly affect the
catalytic activity of the enzyme protein but that the defi-
ciency of sphingomyelinase activity may be due to ab-
normal processing, transport, and/or stability of the mu-
tant enzyme. Recent availability (Ferlinz et al. 1994;
Hurwitz et al. 1994b) of high-affinity, precipitating anti-
ASM antiserum finally enabled us to perform immuno-
precipitation studies on metabolically labeled cultured
fibroblasts. As described elsewhere, COS-1 cells
transfected with wild-type cDNA (Ferlinz et al. 1994),
as well as normal fibroblasts (Hurwitz et al. 1994b),
generate mature forms ofASM from a common catalyti-
cally inactive precursor of 75 kDa. Maturation of the
normal enzyme is achieved mainly by a stepwise mecha-
nism: proteolytic cleavage of the nascent polypeptide
results in a 72-kDa proform inside the endoplasmic re-
ticulum (ER)/Golgi complex, which, after sorting for the
lysosomal pathway, is further processed to the mature
ASM of 70 kDa within -6 h after biosynthesis. The
half-life of the 70-kDa form, to which most of the cata-
lytic activity of ASM can be attributed, is > 12 h. Subse-
quent degradation finally generates a protein of 50
kDa. Besides this regular maturation event, the ASM
precursor is also partially cleaved early inside the ER/
Golgi complex, yielding variable but low amounts of a
57-kDa form of ASM. In the present study, patients'
fibroblasts failed to generate either the 70-kDa or 50-
kDa form of ASM (fig. 3). Immunoprecipitation ofASM
protein from the culture medium showed secretion of
minor amounts of the precursor at the same level as in
the medium of normal fibroblasts (fig. 3). This finding
indicates that, in contrast to I-cell disease fibroblasts,
where a large amount of the ASM precursor is secreted
(Hurwitz et al. 1994b), newly synthesized ASM in the
patient cells is targeted to the lysosomes. On the other
hand, secretion of the mutant ASM precursor into the
culture medium argues against possible misfolding of
the protein followed by precipitation and degradation
inside the ER. Moreover, the early processing, which
results in formation of the 57-kDa form, points to
proper biosynthesis and transport. Collectively, these
data strongly suggest that the mutant ASM is correctly
folded, sorted, and presumably processed to mature ly-
sosomal enzyme but is rapidly degraded inside the acidic
compartments due to structural alterations as the result
of the point mutation. If overexpressed ASM in COS-1
cells overwhelms the limited proteolytic capacity in the
lysosome, significant amounts of the mature mutant pro-
tein may escape rapid and complete hydrolysis. This
would explain the different residual activities in cultured
fibroblasts and transfected COS-1 cells. Similar abnor-
malities of ASM processing have recently been reported
in normal fibroblasts treated with desipramine (Hurwitz
et al. 1994a). Addition of tricyclic antidepressants to
cultured cells is known to affect severely the activity of
ASM but not of most other lysosomal enzymes (Albouz
et al. 1981). This effect can be prevented by preincubat-
ing the cells 18-24 h with leupeptin (Vanier et al. 1986),
shown to inhibit conversion of the 70-kDa into the 50-
kDa form of ASM (Hurwitz et al. 1994a). Addition of
1347
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leupeptin for < 1 week to the mutant Niemann-Pick fi-
broblasts had only minimal effect on in vitro sphingo-
myelinase activities (residual activity remained <1% of
normal). No restoration of activity could be demon-
strated in desipramine-treated cells after 18-h leupeptin
addition (R. Zeitouni and M. T. Vanier, unpublished
data), either, suggesting that proteolytic degradation of
ASM is a more complex process. Further experiments
on ASM metabolism using various human cell types will,
it is hoped, provide more insight into this potential regu-
latory mechanism.
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